- Home
- LPCN vs COCP Comparison
LPCN vs COCP Comparison
Compare LPCN & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- COCP
- Stock Information
- Founded
- LPCN 1997
- COCP 2006
- Country
- LPCN United States
- COCP United States
- Employees
- LPCN N/A
- COCP N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- COCP Health Care
- Exchange
- LPCN Nasdaq
- COCP Nasdaq
- Market Cap
- LPCN 16.1M
- COCP 15.7M
- IPO Year
- LPCN N/A
- COCP N/A
- Fundamental
- Price
- LPCN $3.29
- COCP $1.49
- Analyst Decision
- LPCN Strong Buy
- COCP Strong Buy
- Analyst Count
- LPCN 2
- COCP 1
- Target Price
- LPCN $9.00
- COCP $6.00
- AVG Volume (30 Days)
- LPCN 59.4K
- COCP 26.0K
- Earning Date
- LPCN 08-07-2025
- COCP 08-13-2025
- Dividend Yield
- LPCN N/A
- COCP N/A
- EPS Growth
- LPCN N/A
- COCP N/A
- EPS
- LPCN N/A
- COCP N/A
- Revenue
- LPCN $3,674,834.00
- COCP N/A
- Revenue This Year
- LPCN N/A
- COCP N/A
- Revenue Next Year
- LPCN N/A
- COCP N/A
- P/E Ratio
- LPCN N/A
- COCP N/A
- Revenue Growth
- LPCN N/A
- COCP N/A
- 52 Week Low
- LPCN $2.68
- COCP $1.12
- 52 Week High
- LPCN $8.71
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- LPCN 51.52
- COCP 45.80
- Support Level
- LPCN $3.13
- COCP $1.48
- Resistance Level
- LPCN $3.53
- COCP $1.58
- Average True Range (ATR)
- LPCN 0.24
- COCP 0.10
- MACD
- LPCN 0.01
- COCP -0.01
- Stochastic Oscillator
- LPCN 48.33
- COCP 15.38
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).